Fibrosarcoma: Clinical Trials

10 trials for Fibrosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310Completed 10
Phase 21Completed 1

Follow Fibrosarcoma: new trials by email Literature Review of Fibrosarcoma trials Research Report on Fibrosarcoma

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)1402014-08-122026-06-17
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery - Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Phase 3CompletedChildren's Oncology Group5882007-02-052022-04-28
Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma
radiotherapy - Sarcoma
Phase 3CompletedSheffield Teaching Hospitals NHS Foundation Trust2162006-03-012021-03-18
Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis
conventional surgery, radiation therapy - Sarcoma
Phase 3CompletedAlliance for Clinical Trials in Oncology3702004-08-012016-07-06
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
pegfilgrastim, doxorubicin hydrochloride, ifosfamide - Sarcoma
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC4552003-04-012014-10-27
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
doxorubicin hydrochloride, ifosfamide - Sarcoma
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC7801998-01-012012-01-20
Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma
doxorubicin hydrochloride, etoposide, ifosfamide - Sarcoma
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC3401997-07-012013-09-17
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC3401996-04-012012-07-11
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
filgrastim, doxorubicin hydrochloride, ifosfamide - Endometrial Cancer, Kidney Cancer
Phase 3CompletedEuropean Organisation for Research and Treatment of Cancer - EORTC3501995-02-012014-08-08
Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma
dactinomycin, carboplatin, cyclophosphamide - Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Phase 3CompletedSociete Internationale d'Oncologie Pediatrique4001995-01-012013-12-04

Narrower conditions

Liposarcoma (10)  ·  Sarcoma (10)  ·  Hemangiosarcoma (9)  ·  Histiocytoma, Malignant Fibrous (9)  ·  Leiomyosarcoma (9)  ·  Neurofibrosarcoma (9)  ·  Sarcoma, Synovial (9)  ·  Hemangiopericytoma, Malignant (6)  ·  Malignant mesenchymal tumor (5)  ·  Sarcoma, Alveolar Soft Part (5)  ·  Rhabdomyosarcoma (4)  ·  Chondrosarcoma, Extraskeletal Myxoid (3)  ·  Dermatofibrosarcoma (2)  ·  Endometrial Neoplasms (2)

Broader conditions

Neoplasms (10)  ·  Neoplasms by Histologic Type (10)  ·  Neoplasms, Adipose Tissue (10)  ·  Neoplasms, Connective Tissue (10)  ·  Neoplasms, Connective and Soft Tissue (10)  ·  Neoplasms, Fibrous Tissue (10)  ·  Neoplasms, Nerve Tissue (10)  ·  Histiocytoma (9)  ·  Neoplasms, Muscle Tissue (9)  ·  Neoplasms, Vascular Tissue (9)  ·  Nervous System Diseases (9)  ·  Nervous System Neoplasms (9)  ·  Neurofibroma (9)  ·  Neuromuscular Diseases (9)  ·  Peripheral Nervous System Diseases (9)

Interventions

Ifosfamide (8)  ·  Doxorubicin (7)  ·  Radiotherapy (6)  ·  Chemotherapy, Adjuvant (2)  ·  Etoposide (2)  ·  Filgrastim (2)  ·  Brachytherapy (1)  ·  Carboplatin (1)  ·  Combined Modality Therapy (1)  ·  Cyclophosphamide (1)  ·  Dactinomycin (1)  ·  Diathermy (1)  ·  Epirubicin (1)  ·  Neoadjuvant Therapy (1)  ·  Observation (1)

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC (5)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Children's Oncology Group (1)  ·  National Cancer Institute (NCI) (1)  ·  Sheffield Teaching Hospitals NHS Foundation Trust (1)  ·  Societe Internationale d'Oncologie Pediatrique (1)

Countries

Canada (5)  ·  United Kingdom (5)  ·  Germany (4)  ·  Belgium (3)  ·  Denmark (3)  ·  France (3)  ·  Netherlands (3)  ·  Slovakia (3)  ·  Spain (3)  ·  United States (3)  ·  Austria (2)  ·  Puerto Rico (2)  ·  Switzerland (2)  ·  Australia (1)  ·  Hungary (1)

Top investigators

A.N. Van Geel, MD (1)  ·  Aaron R Weiss (1)  ·  Ian R. Judson, MA, MD, FRCP (1)  ·  Laurence H. Baker, DO, FACOI (1)  ·  M. C. G. Stevens, MD (1)  ·  Martin Robinson, MD (1)  ·  Paul C. Lorigan, MD (1)  ·  Penella J. Woll, MD, PhD (1)  ·  Peter Pisters, MD (1)  ·  Rolf D. Issels, MD, PhD (1)  ·  Ronald H. Blum, MD (1)  ·  Sheri Spunt, MD (1)  ·  Thor A. Alvegard, MD, PhD (1)  ·  Vivien H.C. Bramwell, MB, BS, PhD, FRCP (1)

Results publications

PMID 17634494, PMID 20434400, PMID 22665534, PMID 22954508, PMID 24618336, PMID 24747207, PMID 28391003, PMID 29450452, PMID 30954717, PMID 31786124, PMID 32702309, PMID 32827353, PMID 33548339, PMID 34515544, PMID 34623899, PMID 34666214, PMID 36566574, PMID 37523624, PMID 38757485, PMID 39122389, PMID 41386267, PMID 42035475

NIH funding

U10CA098543 (2), U10CA180830 (1), U10CA180886 (1)